Committee on Energy and Commerce

U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1.	Your Name: David Yoder		
2.	Your Title: Executive Director, Member Care and Benefits		
3.	The Entity(ies) You are Representing: BlueCross BlueShield Associati	on	
4.	Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No
_	<u> </u>	:: 4:-	X
5.	Please list any Federal grants or contracts, or contracts or payments of a foreign government, that you or the entity(ies) you represent have reafter January 1, 2015. Only grants, contracts, or payments related to matter of the hearing must be listed.	ceived o	n or
	Federal Employees Health Benefit Plan Service Benefit Plan		
	2013 \$28.5B		
	2014 \$29.2B		
	2015 \$30.5B		
	2016 \$33.0B		
	2017 \$34.2B		
	2018* \$35.8B		
	Federal Employees Dental and Vision Insurance Program Federal Employees Blue Vision		
	2013 \$91.2M		
	2014 \$99.7M		
	2015 \$107.4M		
	2016 \$123.1M		
	2017 \$139.1M		
	2018* \$146.3M		
	Federal Employees Dental and Vision Insurance Program Federal Employees Blue Dental		
	2013 N/A		

2014	\$32.5M
2015	\$64.6M
2016	\$105.3M
2017	\$135.8M
2018*	\$148.3M

*2018 Management Forecast

6. Please attach your curriculum vitae to your completed disclosure form.

Attached

<

Signature: Date: September 4, 2018

David M. Yoder, PharmD MBA

Education

1998-2000	University of Baltimore. Degree: Masters of Business Administration
1994-1998	University of Maryland School of Pharmacy. Degree: Doctor of Pharmacy
1992-1998	University of Maryland Baltimore County. Pre Pharmacy
1985-1991	U.S. Navy/U.S. Navy Reserves Corpus Christi TX and Baltimore MD

Employment History

August 2017- Present Executive Director Member Care and Benefits, Blue Cross Blue Shield Association Federal Employees Program

In addition to previous responsibilities assumed oversight for FEP's benefit and product development activities including negotiations with the Office of Personnel Management on FEP's product suite along with operational responsibility for implementation of new benefits and programs. Also now responsible for FEP's dental and vision offerings in the FEDVIP marketplace with direct P&L responsibilities of approximately \$240M per year.

August 2010-August 2017 Executive Director of Integrated Care Management, Blue Cross Blue Shield Association Federal Employees Program

In addition to pharmacy administration, assumed responsibility of the case management, disease management, analytics, HEDIS/CAHPS quality improvement and overseas operations for the FEP program. Set and lead the overall care management strategy and oversaw implementation for over 5.3 million federal employees and retirees. Developed and lead new case management models and innovative practices in care management delivery as well as lead the implementation of Patient Centered Medical Home projects in all 36 Blue Cross Blue Shield Plans for Federal Employees. Launched innovations in telemedicine, smart prior authorization, centers of excellence (Blue Distinction) and enhanced care management delivery with remote monitoring for the FEP program. Developed and implemented large scale initiatives to improve select HEDIS metrics through both provider and member engagement activities resulting in substantial increases in key HEDIS rates. Oversee total medical and pharmacy spend of \$32B and administrative budgets of approximately \$20M direct and over \$180M through various Plan level initiatives. Co-chair of the FEP Pharmacy and Medical Policy committee which oversees the formulary development and medical policy development for FEP.

April 2008-August 2010 Executive Director, Pharmacy Programs Blue Cross Blue Shield Federal Employees Program

Responsible for all aspects of pharmacy benefit management for the Federal Employees Program covering over 5.2 million lives. Developed new contract to further take advantage of rebate opportunities and administrative expenses, resulting in savings of over \$1.2B over 3 year contract. Lead and developed transition from 2 tier formulary to 5 tier formulary with special emphasis on specialty drugs. Acted as direct contract officer for the U.S. Government Office of Personnell Management's Contract management team.

September 2005-April 2008 (Formerly Elder Health)

Divisional Vice President, Pharmacy Bravo Health

In charge of pharmacy benefit for Elder Health Inc, a Medicare Advantage HMO (MA-PD) and Prescription Drug Plan (PDP). Lead the first time development and successful implementation of new medicare part D benefits for multi region PDP and multi region MA-PD plans. Responsible for all clinical and operational aspects of drug benefit as well as key financial performance to ensure profitability for the program. Developed Medication Therapy Management (MTM) program to control drug spend in elderly population. Responsible for formulary decisions for part D benefit as well as financial aspects of contracting with manufacturers.

November 2003-August 2005 Vice-President, Pharmacy Services Mid-Atlantic Medical Services (MAMSI) and then United Health Care of the Mid-Atlantic

Directed RFP process and directly negotiated PBM contract with new PBM, Express Scripts. Directed and oversaw transition from Medco Health to Express Scripts with no member or provider interruption. Renegotiated rebate levels with new contract to increase almost 80%. Managed drug trend for 2002-2003 to 2.1%. New programs included PPI step therapy and NSA step therapy. Successfully re-contracted retail pharmacy network resulting in savings of \$1.9M. Continued to refine pharmacy auditing and new clinical programs for 2004 and transition back to Medco with United Health Acquisition of MAMSI. Implemented 2 e-prescribing pilots with over 100 network physicians utilizing two competing technologies.

November 2000-November 2003 Senior Director Pharmacy Services Mid-Atlantic Medical Services (MAMSI)

Responsibilities included those below with the addition of accepting responsibility for MAMSI pharmacy network contracting which included oversight of direct contracts between MAMSI and all network pharmacies (~29,000). Managed departmental budget of \$1.9M and drug spend of \$320M for 960,000 health plan members. Managed department of 49 people, including 9 pharmacist and 9 pharmacy technicians.

December 1999-November 2000 Director, Pharmacy Services Mid-Atlantic Medical Services (MAMSI)

Responsibilities included oversight of all aspects of pharmacy benefit management at Mid-Atlantic Medical Services (MAMSI). Managed clinical staff of 4 pharmacists and 4 technicians in charge of handling all authorizations for MAMSI members. Responsible for call center of 13 representatives taking calls from HMO plan members, Network pharmacies, and physicians. Chaired Pharmacy and Therapeutics committee for MAMSI consisting of 10 physicians and 3 pharmacists. Operational responsibilities consisted of 5 full time employees handling eligibility transmissions to PBM, paying paper claims and trouble shooting of benefit packages. Supervised 2 pharmacy network auditors who conducted on site audits for MAMSI's directly contracted pharmacy network. Managed transition of pharmacy benefits from DPS to Merck-Medco.

August 1998-December 1999 Manager, Clinical Production HomeCall MailRx a Division of Mid Atlantic Medical Services

Manager of MAMSI's Mail order pharmacy division in charge of 7 full time pharmacists dispensing in excess of 5000 rx's per week. Responsibilities also included oversight of drug ordering, inventory maintenance, and computer system manager duties. Division closed with transition to new PBM (Merck-Medco)

Professional Affiliations

Member, Academy of Managed Care 2000-present AMCP Planning and Development Committee Member 2002-2003 Peer Reviewer Journal of Managed Care Pharmacy 2000-present AMCP Ambassador, University of Maryland School of Pharmacy 2003-2005 AMCP Special Projects Committee Member 2004-2006

Teaching

Instructor, Integrated Health Care Delivery, University of Maryland School of Pharmacy 2004-2010 Adjunct professor (Preceptor appointment), University of Maryland School of Pharmacy 1999-present Associate Professor (Non Tenured/non-paid) University of Maryland School of Pharmacy 2016-Present

Publications

Grant W., Yoder D., Mullins CD; Threshold Denial rates in Prior authorization prescription programs. *Expert Review Pharmacoeconomics Outcomes Research*, 4(2), 2004

Mullins CD, Yoder DM, Shaya FT, Taylor TA; Impact of the fourth hurdle on the international pharmaceutical industry. Expert Review Pharmacoeconomics Outcomes Research, 3(2), 169-177, 2003

References: Available upon request